Literature DB >> 19414816

Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C.

Gregory R Moe1, Tamara S Bhandari, Becca A Flitter.   

Abstract

Murine mAbs that were produced by immunization with a vaccine containing the N-propionyl derivative of Neisseria meningitidis group B (MenB) capsular polysaccharide (NPr MBPS) mediate protective responses against MenB but were not reactive with unmodified MBPS or chemically identical human polysialic acid (PSA). Recently, we showed that some of the mAbs were reactive with MBPS derivatives that contain de-N-acetyl sialic acid residues. In this study we evaluated the immunogenicity of de-N-acetyl sialic acid-containing derivatives of PSA (de-N-acetyl PSA) in mice. Four de-N-acetyl PSA Ags were prepared and conjugated to tetanus toxoid, including completely de-N-acetylated PSA. All of the vaccines elicited anti-de-N-acetyl PSA responses (titers >/=1/10,000), but only vaccines enriched for nonreducing end de-N-acetyl residues by treatment with exoneuraminidase or complete de-N-acetylation elicited high titers against the homologous Ag. Also, nonreducing end de-N-acetyl residue-enriched vaccines elicited IgM and IgG Abs of all subclasses that could bind to MenB. The results suggest that the zwitterionic characteristic of neuraminic acid, particularly at the nonreducing end, may be important for processing and presentation mechanisms that stimulate T cells. Abs elicited by all four vaccines were able to activate deposition of human complement proteins and passively protect against challenge by MenB in the infant rat model of meningococcal bacteremia. Some vaccine antisera mediated bactericidal activity against a N. meningitidis group C strain with human complement. Thus, de-N-acetyl PSA Ags are immunogenic and elicit Abs that can be protective against MenB and N. meningitidis group C strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414816      PMCID: PMC2692032          DOI: 10.4049/jimmunol.0803677

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

2.  Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.

Authors:  D Coquillat; J Bruge; B Danve; M Latour; C Hurpin; D Schulz; P Durbec; G Rougon
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants.

Authors:  R E Mandrell; W D Zollinger
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

Review 4.  Development of vaccines against meningococcal disease.

Authors:  Luis Jódar; Ian M Feavers; David Salisbury; Dan M Granoff
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

5.  The changing epidemiology of meningococcal disease in the United States, 1992-1996.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; L Lefkowitz; M L Cartter; R Danila; P Cieslak; K A Shutt; T Popovic; A Schuchat; L H Harrison; A L Reingold
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide.

Authors:  G R Moe; D M Granoff
Journal:  Int Rev Immunol       Date:  2001       Impact factor: 5.311

7.  Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.

Authors:  Jo Anne Welsch; Gregory R Moe; Raffaella Rossi; Jeannette Adu-Bobie; Rino Rappuoli; Dan M Granoff
Journal:  J Infect Dis       Date:  2003-11-19       Impact factor: 5.226

8.  Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR.

Authors:  Brian A Cobb; Dennis L Kasper
Journal:  Glycobiology       Date:  2008-06-04       Impact factor: 4.313

9.  Enzymatic properties of neuraminidases from Arthrobacter ureafaciens.

Authors:  Y Uchida; Y Tsukada; T Sugimori
Journal:  J Biochem       Date:  1979-11       Impact factor: 3.387

10.  Polysaccharide processing and presentation by the MHCII pathway.

Authors:  Brian A Cobb; Qun Wang; Arthur O Tzianabos; Dennis L Kasper
Journal:  Cell       Date:  2004-05-28       Impact factor: 41.582

View more
  14 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  De-N-acetylated sialic acid is immunogenic and elicits antibodies that are protective against Neisseria meningitidis.

Authors:  Gregory R Moe; Becca A Flitter; Jessica Y Ing; Tamara S Bhandari; Hardeep Kaur
Journal:  Vaccimonitor       Date:  2009

3.  The expression profile of de-N-acetyl polysialic acid (NeuPSA) in normal and diseased human tissue.

Authors:  Taizo A Nakano; Lindsay M Steirer; Gregory R Moe
Journal:  J Biol Chem       Date:  2011-09-26       Impact factor: 5.157

4.  Bacterial Glycoengineering as a Biosynthetic Route to Customized Glycomolecules.

Authors:  Laura E Yates; Dominic C Mills; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

5.  Evidence for rosettes as an unrecognized stage in the life cycle of Leishmania parasites.

Authors:  David M Iovannisci; C Paul Plested; Gregory R Moe
Journal:  J Eukaryot Microbiol       Date:  2010-08-05       Impact factor: 3.346

6.  Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group B.

Authors:  Becca A Flitter; Jessica Y Ing; Gregory R Moe
Journal:  Vaccine       Date:  2010-07-15       Impact factor: 3.641

7.  Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies.

Authors:  Jenny L Valentine; Linxiao Chen; Emily C Perregaux; Kevin B Weyant; Joseph A Rosenthal; Christian Heiss; Parastoo Azadi; Adam C Fisher; David Putnam; Gregory R Moe; Judith H Merritt; Matthew P DeLisa
Journal:  Cell Chem Biol       Date:  2016-06-23       Impact factor: 8.116

8.  Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathways.

Authors:  Cynthia Calzas; Guillaume Goyette-Desjardins; Paul Lemire; Fleur Gagnon; Claude Lachance; Marie-Rose Van Calsteren; Mariela Segura
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

Review 9.  Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules.

Authors:  Brady F Cress; Jacob A Englaender; Wenqin He; Dennis Kasper; Robert J Linhardt; Mattheos A G Koffas
Journal:  FEMS Microbiol Rev       Date:  2014-01-27       Impact factor: 16.408

Review 10.  Exploration of the Sialic Acid World.

Authors:  Roland Schauer; Johannis P Kamerling
Journal:  Adv Carbohydr Chem Biochem       Date:  2018-11-28       Impact factor: 12.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.